PUBLIC HEALTH AND ECONOMIC IMPACT OF BIVALENT RSVPREF VACCINATION AMONG ADULTS IN DENMARK
Author(s)
Jeppe Berger, MSc1, Mette Skovdal, MSc1, Erin Quinn, BS2, Mary MacKinnon, BS2, Ahuva Averin, MPP2, Elizabeth Begier, MD3, Diana Mendes, PhD4.
1Pfizer Denmark, Ballerup, Denmark, 2Avalere Health, Washington, DC, USA, 3Pfizer Inc, Ireland, Dublin, Ireland, 4Pfizer UK, Ltd, Tadworth, United Kingdom.
1Pfizer Denmark, Ballerup, Denmark, 2Avalere Health, Washington, DC, USA, 3Pfizer Inc, Ireland, Dublin, Ireland, 4Pfizer UK, Ltd, Tadworth, United Kingdom.
OBJECTIVES: Respiratory syncytial virus (RSV) is a major cause of acute illness in older adults. First-season data from DAN-RSV, the largest pragmatic individually randomised RSV vaccine trial to date, suggest that the burden of RSV-attributable cardiorespiratory hospitalizations has been previously underestimated. Based on these latest data, we estimated the potential public health and economic impact of bivalent RSVpreF vaccination among adults aged ≥60 years in Denmark.
METHODS: A cohort model with Markov-type process was employed to estimate clinical and economic outcomes of hospitalised RSV over a 5-year time horizon, with and without use of RSVpreF (single dose administered in model year 1). Model inputs were mostly based on Danish publicly available data. Clinical outcomes included rates of RSV-attributable and all-cause cardiorespiratory hospitalizations and RSV-attributable deaths. Medical care costs of hospitalized RSV were also included. Effectiveness of bivalent RSVpreF against RSV-attributable hospitalization was based on real-world data. Vaccine uptake was 76% based on 2024/25 influenza coverage in Denmark. A sensitivity analysis evaluated preventable disease burden among persons with chronic obstructive pulmonary disease (COPD).
RESULTS: Without vaccination among adults aged ≥60 years in Denmark (N=1,663,469), there were 25,638 hospitalizations and 1,436 RSV-associated deaths; total cost of medical care for RSV-attributable hospitalisations was €216 million. A single dose of RSVpreF among adults aged ≥60 years (1.26M doses administered) prevented 11,967 hospitalizations and 670 deaths (NNV: 105 and 1,881 respectively), reducing medical care costs by €101 million over the 5-year modelling horizon. Persons with COPD (n=275,528) accounted for 20% of prevented hospitalizations and deaths.
CONCLUSIONS: RSVpreF has the potential to substantially reduce RSV-attributable cardiorespiratory hospitalizations in Denmark, representing a considerable reduction in medical care costs. COPD patients are among several risk groups who are highly affected by RSV and would benefit most from vaccination. A broader recommendation for adults aged ≥60 would yield substantially greater public health benefits.
METHODS: A cohort model with Markov-type process was employed to estimate clinical and economic outcomes of hospitalised RSV over a 5-year time horizon, with and without use of RSVpreF (single dose administered in model year 1). Model inputs were mostly based on Danish publicly available data. Clinical outcomes included rates of RSV-attributable and all-cause cardiorespiratory hospitalizations and RSV-attributable deaths. Medical care costs of hospitalized RSV were also included. Effectiveness of bivalent RSVpreF against RSV-attributable hospitalization was based on real-world data. Vaccine uptake was 76% based on 2024/25 influenza coverage in Denmark. A sensitivity analysis evaluated preventable disease burden among persons with chronic obstructive pulmonary disease (COPD).
RESULTS: Without vaccination among adults aged ≥60 years in Denmark (N=1,663,469), there were 25,638 hospitalizations and 1,436 RSV-associated deaths; total cost of medical care for RSV-attributable hospitalisations was €216 million. A single dose of RSVpreF among adults aged ≥60 years (1.26M doses administered) prevented 11,967 hospitalizations and 670 deaths (NNV: 105 and 1,881 respectively), reducing medical care costs by €101 million over the 5-year modelling horizon. Persons with COPD (n=275,528) accounted for 20% of prevented hospitalizations and deaths.
CONCLUSIONS: RSVpreF has the potential to substantially reduce RSV-attributable cardiorespiratory hospitalizations in Denmark, representing a considerable reduction in medical care costs. COPD patients are among several risk groups who are highly affected by RSV and would benefit most from vaccination. A broader recommendation for adults aged ≥60 would yield substantially greater public health benefits.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE444
Topic
Clinical Outcomes, Economic Evaluation, Epidemiology & Public Health
Disease
Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory), Vaccines